Aller au contenu

    Article de Karim Aly, PDG de notre partenaire Noze: Analyse basée sur la respiration : révolutionner le dépistage des maladies pour un avenir plus sain

    (Cet article est disponible exclusivement en Anglais)

    Despite significant progress in disease testing methodologies, notable deficiencies persist. Misdiagnosis, characterized by the detection of false positives, is prevalent across various screening procedures. Moreover, many severe illnesses currently require expensive, invasive tests that are frequently inaccessible to patients. Compounding the issue, certain diseases with non-trivial morbidity and mortality rates lack a universally accepted screening protocol. However, breath-based screening tests hold promise to fundamentally change this reality.

    Well before the onset of physical symptoms, the body undergoes metabolic changes in response to a disease resulting in the production of a distinct mix of volatile organic compounds (VOCs). This combination of VOCs represents a distinct “scentprint” indicative of the disease and is detectable in breath samples. Targeting these breath scentprints allows for a real-time, noninvasive method for disease screening, offering numerous benefits. Perhaps most notably, breath-based screening can help optimize clinical pathways by facilitating earlier and more effective referrals for confirmatory testing, leading to timelier interventions and improved patient outcomes. Thanks to technological innovation over the past two decades, such testing is now becoming a viable reality.

    To appreciate the far-reaching implications of breath-based screening, let’s explore three prevalent, potentially life-threatening diseases, each of which poses unique screening hurdles. Subsequently, we’ll delve into how breath-based analysis can help overcome those challenges.